Assessment of Rates of Acute Adverse Reactions to Gadobenate Dimeglumine: Review of More Than 130,000 Administrations in 7.5 Years

Abstract

Rates of adverse reactions to gadobenate dimeglumine recorded over 7.5 years were comparable to those reported for other gadolinium-based contrast agents examined over smaller time ranges and populations. The findings reinforce the relatively robust safety profile of this agent.